Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Miners power Footsie gains

Mon, 09th Nov 2009 16:31

Mining stocks were at the vanguard of a strong advance from FTSE 100 as commodity prices were boosted by plans outlined by world leaders over the weekend to continue with stimulus measures.Kazakhmys, Fresnillo, Rio Tinto and Vedanta were some of the best performers in the mining sector.Mining giant Anglo American has added former Sainsbury chairman, Sir Philip Hampton, to the board in a non-executive role. Hampton has been chairman of Royal Bank of Scotland (RBS) since February 2009. After all the waiting and speculation, the formal bid for Cadbury from US group Kraft Foods proved a disappointment.Kraft formally announced a bid for Cadbury on the same terms as the indicative offer announced at the beginning of September. Not surprisingly, the Cadbury board gave the offer short shrift, noting that the terms of 300p cash plus 0.2589 Kraft Foods shares for every Cadbury share actually value each Cadbury share at a lower value now than when the bid terms were first mooted, thanks to the slide in Kraft's share price in the intervening weeks. Cadbury shares initially tumbled from just below 770p to just below 745p on the announcement of the bid terms but later moved back into the blue. The Kraft terms value each Cadbury share at 717p based on Friday's closing share price for Kraft.Prudential went well in a buoyant insurance sector after ING upped its price target for the stock from 392p to 584p.Cash-strapped bank Royal Bank of Scotland is also in demand after week-end analysis of last week's results and government asset protection scheme announcement.Inmarsat was on a high after the satellite operator lifted profits by nearly a third over the past three months. Revenue overall in the three months to September rose by 8.7% to $176.7m (2008: $162.5m). Profit before tax rose by 31% to $70m. Free cash flow rose 6% to $102.9m (2008: $54.0m).Fellow Footsie stock G4S fell, however, after it said things have been steady at the security services firm since August's interims. Operating profit for the first nine months of 2009 was up 25% at actual exchange rates and revenue rose by 23%. At constant exchange rates, profit rose 12% and revenue by 9%.Insurer and reinsurer Beazley has seen strong growth in premiums written this year, even after it pushed through rate increases. Gross premiums written in the first nine months of 2009 rose 45% to £861.9m from £595.4m in the first nine months of last year.Hiscox was in confident mood after boosting premium income by 31.7% in the first nine months of 2009, giving the specialist insurer "good reasons to be optimistic".Sales slumped further at Aer Lingus over the past three months with revenue down by nearly 10% as fares came under heavy pressure both on short-haul and long-haul flights.Oil and gas production levels were both higher in the third quarter at energy company JKX Oil and Gas. Total production in the third quarter of 2009 rose to 13,657 barrels of oil equivalent per day (boepd), up 24% from 10,978 boepd in the same period of 2008.Metal basher IMI has made a thumping gain after saying it expects earnings this year to come in " materially higher" than previously forecast as higher margins have offset a sharp fall in revenues.Shares in online poker giant PartyGaming have come up trumps following the group's purchase of the owner of the World Poker Tour brand. The company has paid £12.3m in cash for WPT Enterprises. Engineering and construction group Costain has been appointed to assist with a roadworks programme in the Midlands arising from the government's fiscal stimulus plan.The share price of respiratory disease drug developer Synairgen more than doubled in early trading on Monday after lab test suggested its inhaled interferon beta product could combat swine flu.FTSE 100 - RisersRoyal Bank of Scotland Group (RBS) 39.40p +6.30%Kazakhmys (KAZ) 1,286.00p +6.02%Prudential (PRU) 608.00p +5.19%Xstrata (XTA) 1,011.00p +5.04%Antofagasta (ANTO) 893.00p +4.63%Vedanta Resources (VED) 2,367.00p +4.60%Inmarsat (ISAT) 621.00p +4.46%Fresnillo (FRES) 875.00p +4.35%Legal & General Group (LGEN) 83.25p +4.32%Rio Tinto (RIO) 3,042.00p +4.29%FTSE 100 - FallersCable & Wireless (CW.) 136.80p -1.58%G4S (GFS) 249.90p -1.15%Next (NXT) 1,967.00p -0.41%WPP Group (WPP) 568.50p +0.09%Severn Trent (SVT) 946.50p +0.11%SEGRO (SGRO) 346.30p +0.14%Capita Group (CPI) 768.50p +0.20%British American Tobacco (BATS) 1,963.00p +0.20%Tesco (TSCO) 418.85p +0.20%British Airways (BAY) 199.30p +0.25%FTSE 250 - RisersIMI (IMI) 529.50p +15.16%Yell Group (YELL) 48.00p +8.72%Punch Taverns (PUB) 93.50p +6.13%Cookson Group (CKSN) 393.60p +5.52%Ferrexpo (FXPO) 168.20p +4.99%Dunelm Group (DNLM) 390.00p +4.64%Bodycote (BOY) 172.50p +4.61%Chloride Group (CHLD) 173.50p +4.58%Talvivaara Mining Company (TALV) 380.30p +4.45%Petropavlovsk (POG) 1,284.00p +4.39%FTSE 250 - FallersForth Ports (FPT) 1,135.00p -4.46%Fidessa (FDSA) 1,217.00p -3.11%Filtrona PLC (FLTR) 174.50p -3.06%Berkeley Group Holdings Units (BKG) 831.00p -2.86%Stobart Group (STOB) 124.50p -2.73%Cranswick (CWK) 680.50p -2.23%Genus (GNS) 634.50p -2.08%Go-Ahead Group (GOG) 1,365.00p -1.87%Avis Europe (AVE) 25.93p -1.78%Morgan Sindall (MGNS) 550.50p -1.70%
More News
25 Sep 2014 11:03

Synairgen Swings To Profit On Transformational AstraZeneca Deal

Read more
4 Jul 2014 12:11

Synairgen raises funds to develop AstraZeneca drug

Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is

Read more
4 Jul 2014 07:21

UK MORNING BRIEFING: William Hill Promotes From Within

Read more
4 Jul 2014 06:47

Synairgen Raises GBP5.3 Million In Share Placing At 50 Pence

Read more
15 Jun 2014 12:28

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff

Read more
12 Jun 2014 16:37

MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions

LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.

Read more

12 Jun 2014 10:23

TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014

LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more

12 Jun 2014 08:25

London open: Mining stocks pull FTSE 100 lower ahead of data

- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound

Read more
12 Jun 2014 07:42

AstraZeneca signs licence deal with Synairgen

British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de

Read more
12 Jun 2014 07:36

UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen

LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.

AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology

Read more
12 Jun 2014 06:52

AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen

LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections

Read more
20 Mar 2014 12:47

Synairgen Pretax Loss Narrows On Expenses

LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye

Read more
5 Mar 2014 11:31

Synairgen Jumps As It Raises Cash While Progressing Licensing Talks

LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery

Read more
5 Mar 2014 08:31

UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool

LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.

Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi

Read more
5 Dec 2012 11:10

Synairgen reports 'significant progress'

Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account